Previously, Kono et al, performed several studies to determine the exact mechanism of trastuzumab, and they demonstrated that DCs pulsed with HER-2/neu-derived peptides can induce specific T-cell responses in patients with gastric cancer when these are pre-treated with trastuzumab [12]. Here, ERBB2 is linked to gastric cancer.